Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis

被引：6

作者：

Haeussler, Katrin ^{[1
]}

Wang, Xuan ^{[2
]}

Winfree, Katherine B. ^{[3
]}

D'yachkova, Yulia ^{[4
]}

Traore, Sory ^{[5
]}

Puri, Tarun ^{[6
]}

Thom, Howard ^{[7
]}

Papagiannopoulos, Christos ^{[2
]}

Nassim, Maria ^{[1
]}

Taipale, Kaisa ^{[8
]}

机构：

[1] ICON Plc, D-81829 Munich, Germany

[2] ICON Plc, S-11121 Stockholm, Sweden

[3] Eli Lilly & Co, Indianapolis, IN 46285 USA

[4] Eli Lilly GmbH, Vienna, Austria

[5] Eli Lilly & Co, Arlington Sq, Basingstoke, Hants, England

[6] Eli Lilly & Co India Pvt Ltd, Gurgaon, India

[7] Univ Bristol, Bristol Med Sch Populat Hlth Sci, Bristol, Avon, England

[8] Oy Eli Lilly Finland Ab, Helsinki, Finland

来源：

FUTURE ONCOLOGY | 2022年 / 18卷 / 16期

关键词：

EGFR positive; network meta-analysis; non-small-cell lung cancer; progression-free survival; systematic literature review; tyrosine kinase inhibitors; LONG-TERM RESPONDERS; RANDOMIZED PHASE-II; PLUS NSCLC ANALYSIS; QUALITY-OF-LIFE; GEFITINIB MAINTENANCE THERAPY; PATIENT-REPORTED OUTCOMES; RECEPTOR GENE-MUTATIONS; OPEN-LABEL; ASIAN PATIENTS; JAPANESE PATIENTS;

D O I：

10.2217/fon-2021-0885

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC), with a focus on ramucirumab + erlotinib. Methods: In the absence of head-to-head studies, a Bayesian network meta-analysis was conducted using randomized clinical trial data to evaluate first-line systemic therapies with erlotinib/gefitinib as the reference treatment. Results: For progression-free survival (PFS), ramucirumab + erlotinib was comparable to osimertinib and dacomitinib in the primary analysis. Conclusion: The analysis showed ramucirumab + erlotinib efficacy to be comparable to best-in-class treatment options for previously untreated patients with EGFRm(+) advanced NSCLC. Registration information: PROSPERO ID:

引用

页码：2007 / 2028

页数：22

共 105 条

[81] Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902 [J].

Sugawara, S. ;

Oizumi, S. ;

Minato, K. ;

Harada, T. ;

Inoue, A. ;

Fujita, Y. ;

Maemondo, M. ;

Yoshizawa, H. ;

Ito, K. ;

Gemma, A. ;

Nishitsuji, M. ;

Harada, M. ;

Isobe, H. ;

Kinoshita, I. ;

Morita, S. ;

Kobayashi, K. ;

Hagiwara, K. ;

Kurihara, M. ;

Nukiwa, T. .

ANNALS OF ONCOLOGY, 2015, 26 (05) :888-894

[82] Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].

Sung, Hyuna ;

Ferlay, Jacques ;

Siegel, Rebecca L. ;

Laversanne, Mathieu ;

Soerjomataram, Isabelle ;

Jemal, Ahmedin ;

Bray, Freddie .

CA-A CANCER JOURNAL FOR CLINICIANS, 2021, 71 (03) :209-249

[83] Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer [J].

Thomas, Michael ;

Fischer, Juergen ;

Andreas, Stefan ;

Kortsik, Cornelius ;

Grah, Christian ;

Serke, Monika ;

von Eiff, Michael ;

Witt, Christian ;

Kollmeier, Jens ;

Mueller, Ernst ;

Schenk, Michael ;

Schroeder, Michael ;

Villalobos, Matthias ;

Reinmuth, Niels ;

Penzel, Roland ;

Schnabel, Philipp ;

Acker, Thomas ;

Reuss, Alexander ;

Wolf, Martin .

EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (01) :219-229

[84] Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial [J].

Woods, Beth S. ;

Hawkins, Neil ;

Scott, David A. .

BMC MEDICAL RESEARCH METHODOLOGY, 2010, 10

[85]

Wu BG., 2018, ONCOLOGIST, V26, P26

[86]

Wu Y, 2014, J THORAC ONCOL, V9, pS37

[87] First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study [J].

Wu, Y. -L. ;

Zhou, C. ;

Liam, C. -K. ;

Wu, G. ;

Liu, X. ;

Zhong, Z. ;

Lu, S. ;

Cheng, Y. ;

Han, B. ;

Chen, L. ;

Huang, C. ;

Qin, S. ;

Zhu, Y. ;

Pan, H. ;

Liang, H. ;

Li, E. ;

Jiang, G. ;

How, S. H. ;

Fernando, M. C. L. ;

Zhang, Y. ;

Xia, F. ;

Zuo, Y. .

ANNALS OF ONCOLOGY, 2015, 26 (09) :1883-1889

[88] Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study [J].

Wu, Yi-Long ;

Zhou, Caicun ;

Lu, Shun ;

Qin, Shukui ;

Pan, Hongming ;

Wu, Gang ;

Cheng, Ying ;

Liu, Xiaoqing ;

Han, Baohui ;

Zhu, Yunzhong ;

Zhong, Zhaoyang ;

Huang, Cheng ;

Chen, Lei ;

Liang, Houjie ;

Li, Enxiao ;

Jiang, Guoliang .

LUNG CANCER, 2019, 130 :18-24

[89] Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials [J].

Wu, Yi-Long ;

Sequist, Lecia V. ;

Tan, Eng-Huat ;

Geater, Sarayut L. ;

Orlov, Sergey ;

Zhang, Li ;

Lee, Ki Hyeong ;

Tsai, Chun-Ming ;

Kato, Terufumi ;

Barrios, Carlos H. ;

Schuler, Martin ;

Hirsh, Vera ;

Yamamoto, Nobuyuki ;

O'Byrne, Kenneth ;

Boyer, Michael ;

Mok, Tony ;

Peil, Barbara ;

Marten, Angela ;

Yang, James Chih-Hsin ;

Paz-Ares, Luis ;

Park, Keunchil .

CLINICAL LUNG CANCER, 2018, 19 (04) :E465-E479

[90] Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) [J].

Wu, Yi-Long ;

Hirsh, Vera ;

Sequist, Lecia V. ;

Hu, Cheng-Ping ;

Feng, Jifeng ;

Lu, Shun ;

Huang, Yunchao ;

Schuler, Martin ;

Mok, Tony ;

Yamamoto, Nobuyuki ;

O'Byrne, Kenneth ;

Geater, Sarayut L. ;

Zhou, Caicun ;

Massey, Dan ;

Maerten, Angela ;

Lungershausen, Juliane ;

Yang, James Chih-Hsin .

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2018, 11 (01) :131-141

← 2 3 4 5 6 7 8 9 10 11 →